Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

• Published in: Revista da Sociedade Brasileira de Medicina Tropical
• Main Authors: José Wagner Leonel Tavares-Júnior, José Carlos Jucá Pompeu Filho, Luiz Eduardo Garcia Galvão
• Format: Article in Journal/Newspaper
• Language: English
• Published: Sociedade Brasileira de Medicina Tropical (SBMT) 2023
• Subjects: COVID-19; Nirmatrelvir/ritonavir; Erythema multiforme; Arctic medicine. Tropical medicine; RC955-962; Arctic
• Online Access: https://doi.org/10.1590/0037-8682-0008-2023; https://doaj.org/article/989902889cca4bf5be6f5f523262b6ed

ABSTRACT Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigations showed positive coronavirus disease (COVID-19) based on polymerase chain reaction assay, and she received a 5-day regimen of nirmatrelvir/ritonavir. We observed development of EM after this treatment and initiated prednisone (1 mg/kg) therapy, which led to rapid improvement. Our study is the first to report EM in a patient with COVID-19, who received nirmatrelvir/ritonavir and showed a favorable response.